Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same
The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.
1. An isolated antibody that specifically binds to an epitope on a CD43 or a carcinoembryonic antigen (CEA) expressed by a nonhematopoietic cancer cell, said antibody comprising a heavy chain and a light chain, wherein
(a) the heavy chain comprises a heavy chain variable region comprising the three complementary determining regions (CDRs) from the amino acid sequence of SEQ ID NO:1, and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:9, wherein the hinge region of the heavy chain constant region comprises at least one amino acid insertion, deletion or substitution; and
(b) the light chain comprises a light chain variable region comprising the three complementary determining regions (CDRs) from the amino acid sequence of SEQ ID NO:2, and a light chain constant region comprising the amino acid sequence of SEQ ID NO:10 and further comprising at least one amino acid insertion in the constant region.
2. The antibody of claim 1 , wherein the antibody is a humanized antibody.
3. The antibody of claim 1 , wherein the antibody is a chimeric antibody.
4. An antibody that specifically binds to an epitope on a CD43 or a carcinoembryonic antigen (CEA) expressed by a nonhematopoietic cancer cell, said antibody comprising a heavy chain and a light chain, wherein
(a) the heavy chain comprises a heavy chain variable region comprising the three complementary determining regions (CDRs) from the amino acid sequence of SEQ ID NO:1, and a heavy chain constant region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:11-30, and
(b) the light chain comprises a light chain variable region comprising the three complementary determining regions (CDRs) from the amino acid sequence of SEQ ID NO:2, and a light chain constant region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:10 and 31-37.
5. The antibody of claim 4 , wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:27.
6. The antibody of claim 4 , wherein the heavy chain variable region comprises the amino acid sequence of residues 20-137 of SEQ ID NO:1 and the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:27, and the light chain variable region comprises the amino acid sequence of residues 20-131 of SEQ ID NO:2 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:10.
7. The antibody of claim 4 , wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:29.
8. The antibody of claim 4 , wherein the heavy chain variable region comprises the amino acid sequence of residues 20-137 of SEQ ID NO:1 and the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:29, and the light chain variable region comprises the amino acid sequence of residues 20-131 of SEQ ID NO:2 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:34.
9. The antibody of claim 4 , wherein the heavy chain variable region comprises the amino acid sequence of residues 20-137 of SEQ ID NO:1 and the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:29, and the light chain variable region comprises the amino acid sequence of residues 20-131 of SEQ ID NO:2 and the light chain constant region comprises the amino acid sequence of SEQ ID NO:35.
10. A pharmaceutical composition comprising the antibody of claim 1 , and a pharmaceutically acceptable carrier.
11. An antibody that specifically binds to an epitope on a CD43 or a carcinoembryonic antigen (CEA) expressed by a nonhematopoietic cancer cell, wherein the antibody is produced by a method comprising expressing one or more polynucleotides encoding the heavy and light chain of the antibody of claim 1 in a host cell, and recovering the antibody produced by the host cell.
12. The antibody of claim 4 , wherein the antibody is a humanized antibody.
13. The antibody of claim 12 , wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:27, and the light chain constant region comprises the amino acid sequence of SEQ ID NO:10.
14. The antibody of claim 12 , wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:29, and the light chain constant region comprises the amino acid sequence of SEQ ID NO:34.
15. The antibody of claim 12 , wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:29, and the light chain constant region comprises the amino acid sequence of SEQ ID NO:35.
16. The antibody of claim 4 , wherein the antibody is a chimeric antibody.
17. A pharmaceutical composition comprising the antibody of claim 4 , and a pharmaceutically acceptable carrier.
18. An antibody that specifically binds to an epitope on a CD43 or a carcinoembryonic antigen (CEA) expressed by a nonhematopoietic cancer cell, wherein the antibody is produced by a method comprising:
(1) expressing in a host cell, one or more polynucleotides comprising
(a) a nucleic acid sequence encoding a heavy chain comprising a heavy chain variable region comprising the three CDRs from the amino acid sequence of SEQ ID NO:1 and a heavy chain constant region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:11-30; and
(b) a nucleic acid sequence encoding a light chain comprising a light chain variable region comprising the three CDRs from the amino acid sequence of SEQ ID NO:2 and a constant region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:10 and 31-37,
wherein the heavy chain and the light chain are expressed in said host cell;
(2) recovering the antibody expressed by said host cell.
19. A kit comprising a pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
20. The kit of claim 19 , wherein the kit further comprises a package insert comprising instructions for administering the pharmaceutical composition in conjunction with another anti-cancer agent to an individual for treating nonhematopoietic cancer.
21. A kit comprising a first pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier, and a second pharmaceutical composition comprising another anti-cancer agent.
22. The kit of claim 19 , wherein the kit further comprises a package insert comprising instructions for administering an effective amount of the pharmaceutical composition to an individual for treating nonhematopoietic cancer.
23. The kit of claim 21 , wherein the kit further comprises a package insert comprising instructions for administering the first pharmaceutical composition and the second pharmaceutical composition in conjunction to an individual for treating nonhematopoietic cancer.
24. A kit comprising a pharmaceutical composition comprising the antibody of claim 4 and a pharmaceutically acceptable carrier.
25. The kit of claim 24 , wherein the kit further comprises a package insert comprising instructions for administering an effective amount of the pharmaceutical composition to an individual for treating nonhematopoietic cancer.
26. The kit of claim 24 , wherein the kit further comprises a package insert comprising instructions for administering the pharmaceutical composition in conjunction with another anti-cancer agent to an individual for treating nonhematopoietic cancer.
27. A kit comprising a first pharmaceutical composition comprising the antibody of claim 4 and a pharmaceutically acceptable carrier, and a second pharmaceutical composition comprising another anti-cancer agent.
28. The kit of claim 27 , wherein the kit further comprises a package insert comprising instructions for administering the first pharmaceutical composition and the second pharmaceutical composition in conjunction to an individual for treating nonhematopoietic cancer.
29. A method of producing an antibody, comprising culturing a host cell comprising one or more polynucleotides encoding the heavy and light chain of the antibody of claim 1 , wherein the antibody is produced in the host cell, and recovering the antibody from the cell culture.
30. A method of producing an antibody, comprising expressing in a host cell,
(a) a polynucleotide comprising a nucleic acid sequence encoding a heavy chain comprising a heavy chain variable region comprising the three CDRs from the amino acid sequence of SEQ ID NO:1 and a heavy chain constant region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:11-30; and
(b) a polynucleotide comprising a nucleic acid sequence encoding a light chain comprising a light chain variable region comprising the three CDRs from the amino acid sequence of SEQ ID NO:2 and a constant region comprising the amino acid sequence selected from the group consisting of SEQ ID NOS:10 and 31-37,
wherein the polynucleotides encoding the heavy chain and light chain are co-expressed in said host cell.
31. The method of claim 30 , wherein the antibody is isolated from the cell culture.
32. A method of producing an antibody, comprising culturing a host cell comprising one or more polynucleotides encoding the heavy and light chain of the antibody of claim 4 , wherein the antibody is produced in the host cell; and recovering the antibody from the cell culture.